Pregnenolone methyl ether - Mapreg
Alternative Names: 3-methoxy-pregnenolone - Mapreg; MAP-4343Latest Information Update: 28 Apr 2022
At a glance
- Originator Mapreg
- Class Antidepressants; Drug withdrawal therapies; Steroids
- Mechanism of Action Microtubule-associated protein stimulants; Tubulin polymerisation promoters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Depressive disorders
- No development reported Brain injuries; Spinal cord injuries; Substance-related disorders
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Substance-related disorders in France (PO)
- 23 Feb 2022 Mapreg withdrew a phase II trial prior to enrolment due to the lack of feasibility because of COVID-19 pandemic for Alcoholism in USA (PO) (NCT04157114)
- 28 Oct 2021 No recent reports of development identified for phase-I development in Brain injuries in France (SC, Injection)